|  Help  |  About  |  Contact Us

Publication : Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis.

First Author  Canales-Herrerias P Year  2024
Journal  Sci Immunol Volume  9
Issue  94 Pages  eadg7549
PubMed ID  38640252 Mgi Jnum  J:358612
Mgi Id  MGI:7782806 Doi  10.1126/sciimmunol.adg7549
Citation  Canales-Herrerias P, et al. (2024) Gut-associated lymphoid tissue attrition associates with response to anti-alpha4beta7 therapy in ulcerative colitis. Sci Immunol 9(94):eadg7549
abstractText  Vedolizumab (VDZ) is a first-line treatment in ulcerative colitis (UC) that targets the alpha4beta7- mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) axis. To determine the mechanisms of action of VDZ, we examined five distinct cohorts of patients with UC. A decrease in naive B and T cells in the intestines and gut-homing (beta7(+)) plasmablasts in circulation of VDZ-treated patients suggested that VDZ targets gut-associated lymphoid tissue (GALT). Anti-alpha4beta7 blockade in wild-type and photoconvertible (KikGR) mice confirmed a loss of GALT size and cellularity because of impaired cellular entry. In VDZ-treated patients with UC, treatment responders demonstrated reduced intestinal lymphoid aggregate size and follicle organization and a reduction of beta7(+)IgG(+) plasmablasts in circulation, as well as IgG(+) plasma cells and FcgammaR-dependent signaling in the intestine. GALT targeting represents a previously unappreciated mechanism of action of alpha4beta7-targeted therapies, with major implications for this therapeutic paradigm in UC.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

4 Bio Entities

0 Expression